Product Name:
PRMT5-pT634
Product Number:
ab-pn549
Target Full Name: Protein arginine N-methyltransferase 5
Target Alias: 72 kDa ICln-binding protein; ANM5; Histone-arginine N-methyltransferase PRMT5; HMT1 hnRNP methyltransferase-like 5; HRMT1L5; IBP72; Jak-binding protein 1; JBP1; PRMT5; protein arginine methyltransferase 5; Protein arginine N-methyltransferase 5; Shk1 kinase-binding protein 1 homolog; SKB1; SKB1 homolog; SKB1Hs
Product Type Specific: PRMT5 phosphosite-specific antibody
Antibody Code: PN549
Antibody Target Type: Phosphosite-specific
Antibody Phosphosite: T634
Protein UniProt: O14744
Protein SigNET: O14744
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Human PRMT5 sequence peptide Cat. No.: PE-04ARI90
Antibody Immunogen Sequence: GRSY(pT)IGL(bA)C
Antibody Immunogen Description: Corresponds to amino acid residues G630 to L637; At the C-terminus of the protein.
Production Method: Corresponds to amino acid residues G630 to L637; At the C-terminus of the protein.
Antibody Modification: PRMT5 phosphosite-specific antibody
Antibody Concentration: 1 mg/ml
Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 2 µg/ml for immunoblotting
Antibody Species Reactivity: Human
Antibody Positive Control: The observed molecular mass of the processed target protein on SDS-PAGE gels is reported to be around 70-75 kDa.
Antibody Specificity: Very high
Antibody Cross Reactivity: No significant cross-reactive proteins detected in phenylarsine oxide (PAO)+vanadate-treated HeLa cells, EGF-treated A431 cells and insulin-treated MCF7 cells, when these cells were homogenized in SDS-PAGE sample buffer.
Related Product 1: PRMT5-pT634 blocking peptide
Scientific Background: PRMT5 is an arginine methyltransferase that can both catalyze the formation of omega-N monomethylarginine (MMA) and symmetrical dimethylarginine (sDMA), with a preference for the formation of MMA.